CD274 and non-small cell lung carcinoma: Automated image analysis of cell density in non-small cell lung cancer (NSCLC) tumor samples subsequently treated with durvalumab (n = 163; 77% patients previously treated) showed that high baseline combined CD8+/PD-L1+ cell densities (n = 26) were associated with higher overall response rate (ORR = 42%; 95% confidence interval [CI]: 23, 63) than low combined densities (ORR = 7%, 95% CI: 2, 17).